Edap Tms (NASDAQ:EDAP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Edap Tms (NASDAQ:EDAP) to a hold rating in a research report report published on Saturday.

A number of other research analysts also recently weighed in on EDAP. Weiss Ratings reissued a “sell (d-)” rating on shares of Edap Tms in a research note on Monday, December 29th. Jefferies Financial Group reissued a “hold” rating and issued a $2.00 target price on shares of Edap Tms in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.50.

Edap Tms Stock Performance

NASDAQ EDAP opened at $4.91 on Friday. Edap Tms has a 1-year low of $1.21 and a 1-year high of $5.00. The company has a 50 day moving average of $3.46 and a 200-day moving average of $2.56. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.04. The firm has a market cap of $183.58 million, a price-to-earnings ratio of -8.61 and a beta of -0.16.

Hedge Funds Weigh In On Edap Tms

Large investors have recently added to or reduced their stakes in the company. Sage Mountain Advisors LLC bought a new position in Edap Tms in the second quarter valued at approximately $165,000. Leonteq Securities AG acquired a new stake in shares of Edap Tms in the 4th quarter valued at approximately $313,000. Finally, Financial Planning Navigators CORP acquired a new stake in shares of Edap Tms in the 4th quarter valued at approximately $33,000. Institutional investors own 62.74% of the company’s stock.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.